Nordic Life Science 1
TOP STORIES BUSINESS Marcus Schindler, CSO, Novo
Nordisk BUSINE S S D E A L the successful transition for Calliditas to a commercialstage biopharmaceutical company, it states. TARPEYO is approved under accelerated approval based on achieving its primary endpoint of reduction in proteinuria in Part A of the NeflgArd Phase 3 study. The study is an ongoing, randomized, double-blind, placebocontrolled, multicenter study conducted to evaluate the efficacy and safety of TARPEYO 16 mg once daily vs placebo in adult patients with primary IgAN. held company focusing on RNAibased therapeutics. Using its GalXC and GalXC-Plus RNAi technologies, it develops RNAi-based therapies to selectively silence genes that cause or contribute to disease. Dicerna’s RNAi technology platform enables access to intracellular disease targets across hepatic and extrahepatic cell and tissue 10 NORDICLIFESCIENCE.ORG types. In 2019, Novo Nordisk entered a research collaboration with Dicerna to discover and develop RNAi therapies. The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including nonalcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. Novo Nordisk now expects to initiate clinical development with the first target in 2022. Renee Aguiar Lucander, CEO, Calliditas PHOTO JANN LIPKA